PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
May 13, 2016 01:04 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, May 13, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007...
ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2016 AND PROVIDES BUSINESS UPDATE YEAR-TO-DATE
May 12, 2016 01:06 ET
|
Ablynx
REGULATED INFORMATION
Reported positive top line results from first-in-infant Phase I/IIa study of the inhaled anti-RSV Nanobody® (ALX-0171)
Clinical product pipeline expanded with...
ABLYNX REPORTS POSITIVE TOP LINE RESULTS FOR ITS INHALED ANTI-RSV NANOBODY (ALX-0171) IN A PHASE I/IIa STUDY IN INFANTS HOSPITALISED WITH AN RSV INFECTION
May 03, 2016 01:11 ET
|
Ablynx
Primary endpoint of safety and tolerability met
Anti-viral effect demonstrated and encouraging initial indication of therapeutic effect
Results support advancing the programme into a...
ABLYNX ANNOUNCES MILESTONE IN DRUG DISCOVERY COLLABORATION
April 29, 2016 01:04 ET
|
Ablynx
Second Nanobody® targeting a G-protein-coupled receptor (GPCR) enters clinical development
Further positive validation of Ablynx's Nanobody platform and its ability to address complex...
ABLYNX ANNOUNCES WARRANT EXERCISE
April 22, 2016 01:06 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, April 22, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007...
ABLYNX TO RECEIVE AN EU8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS A PHASE I STUDY WITH AN ANTI-CX3CR1 NANOBODY
April 21, 2016 01:05 ET
|
Ablynx
GHENT, Belgium and INGELHEIM, Germany, April 21, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] and Boehringer Ingelheim today announced the initiation of a Phase I study to...
ABLYNX ANNOUNCES WARRANT EXERCISE
March 22, 2016 02:08 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, March 22, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007...
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
March 14, 2016 02:10 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, March 14, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
March 07, 2016 01:04 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, March 7, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...
ABLYNX ANNOUNCES 2015 FULL YEAR RESULTS
February 25, 2016 01:09 ET
|
Ablynx
REGULATED INFORMATION
Key value drivers in pre-clinical and clinical development are progressing well
Conference call and webcast today at 4pm CET/10am EST
GHENT, Belgium, Feb. 25, 2016...